Recursion Pharmaceuticals (NASDAQ:RXRX) CFO Ben Taylor Sells 13,426 Shares

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) CFO Ben Taylor sold 13,426 shares of the firm’s stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $3.08, for a total transaction of $41,352.08. Following the completion of the transaction, the chief financial officer directly owned 1,195,349 shares of the company’s stock, valued at approximately $3,681,674.92. The trade was a 1.11% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Recursion Pharmaceuticals Trading Down 6.9%

Shares of NASDAQ RXRX traded down $0.26 during midday trading on Friday, hitting $3.47. 10,271,253 shares of the company traded hands, compared to its average volume of 21,401,586. The stock has a 50-day moving average price of $4.27 and a 200 day moving average price of $4.78. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.60 and a current ratio of 4.60. The firm has a market cap of $1.80 billion, a P/E ratio of -1.93 and a beta of 0.95. Recursion Pharmaceuticals, Inc. has a 12-month low of $2.98 and a 12-month high of $10.60.

Hedge Funds Weigh In On Recursion Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in RXRX. Brighton Jones LLC increased its stake in Recursion Pharmaceuticals by 49.4% during the fourth quarter. Brighton Jones LLC now owns 20,261 shares of the company’s stock worth $137,000 after acquiring an additional 6,699 shares during the last quarter. Royal Bank of Canada raised its stake in shares of Recursion Pharmaceuticals by 627.6% during the first quarter. Royal Bank of Canada now owns 269,013 shares of the company’s stock valued at $1,423,000 after acquiring an additional 232,038 shares in the last quarter. AQR Capital Management LLC purchased a new position in shares of Recursion Pharmaceuticals during the first quarter valued at $890,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Recursion Pharmaceuticals by 7.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 177,434 shares of the company’s stock worth $953,000 after buying an additional 12,372 shares in the last quarter. Finally, Focus Partners Wealth purchased a new stake in shares of Recursion Pharmaceuticals during the first quarter valued at about $77,000. Hedge funds and other institutional investors own 89.06% of the company’s stock.

Analysts Set New Price Targets

RXRX has been the subject of a number of recent research reports. JPMorgan Chase & Co. upgraded Recursion Pharmaceuticals from a “neutral” rating to an “overweight” rating and boosted their price target for the company from $10.00 to $11.00 in a research note on Wednesday, December 17th. Morgan Stanley set a $11.00 price objective on shares of Recursion Pharmaceuticals in a report on Wednesday, December 17th. Weiss Ratings restated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research report on Thursday, January 22nd. Finally, UBS Group set a $11.00 price target on shares of Recursion Pharmaceuticals in a research report on Wednesday, December 17th. Two equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $9.40.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.